knowledge -WSS

knowledge

author：hotspot 2025-09-29 21:13:04 - browse：2899

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： The high cost of giving birth even with insurance
Next article： Life sciences investors close nearly $6 billion in new funds

WSS

Readout LOUD podcast: How biotech is using artificial intelligence

Biden report: The neurospychology of memory and aging

Biden report: The neurospychology of memory and aging

BioAge raises $170M for combination therapy with Zepbound

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Sarepta Duchenne therapy fails to meet primary endpoint in trial

knowledge

knowledge

knowledge

Medicare details structure of new drug price negotiation program

Key House Republican on health care plans exit from Congress

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare must police algorithms in Medicare Advantage, Dems say

In Memoriam: Notable people who died in 2023

Bill would allow buprenorphine prescription for addiction via telehealth

Duchenne breakthrough therapy leaves behind pioneering families

For Medicare Advantage, Democrats want stronger protections around AI

At least 13 dead in Texas as scorching temps continue

Medicare threatens to cut off funding for HCA's Mission hospital

hotspot

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

All of Us, NIH's precision medicine initiative, gets a big boost

How digital tools helped lower hypertension in marginalized patients

After Sarepta trial failure, Duchenne families brace for more debate

Biden report: The neurospychology of memory and aging

Why did Pfizer dish out millions for a Super Bowl ad?

focus

leisure time

focus

focus